Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €61.60 EUR
Change Today +0.486 / 0.80%
Volume 220.0
8AK On Other Exchanges
As of 1:45 PM 07/30/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

James M. Frates

Chief Financial Officer, Senior Vice President and Treasurer, Alkermes plc
AgeTotal Calculated CompensationThis person is connected to 16 board members in 1 different organizations across 2 different industries.

See Board Relationships
As of Fiscal Year 2014


Mr. James M. Frates, also known as Jim has been the Chief Financial Officer and Treasurer of Alkermes Inc., and Alkermes Plc since June 1998 and serves as its Principal Accounting Officer. Mr. Frates has been a Senior Vice President of Alkermes, Inc. since May 22, 2007. He manages all aspects of finance and helped oversee the 2011 business combination with Elan Drug Technologies (EDT). He has been the Chief Financial Officer, Vice President, Treasurer and Assistant ...

Read Full Background

Corporate Headquarters*

Connaught House
Dublin, Co. Dublin 4


Phone: 353 1 772 8000
Fax: --

Board Members Memberships*

Director, Chairman of Audit Committee and Member of Compensation Committee


MBA 1996
Harvard University
Harvard College

Other Affiliations*

Annual Compensation*

Total Annual Compensation$468,727

Stock Options*

Restricted Stock Awards$530,550
All Other Compensation$13,088
Exercised Options242,978
Exercised Options Value$8,512,597
Exercisable Options438,393
Exercisable Options Value$19,048,852
Unexercisable Options177,500
Unexercisable Options Value$4,985,975
Total Value of Options$32,547,423
Total Number of Options858,871

Total Compensation*

Total Annual Cash Compensation$857,815
Total Short Term Compensation$468,727
Other Long Term Compensation$543,638
Total Calculated Compensation$2,565,396
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
8AK:GR €61.60 EUR +0.486


Herve Hoppenot Chief Executive Officer, President, Director and Member of Non-Management Stock Option Committee
Incyte Corporation
James A. Schoeneck Chief Executive Officer, President and Director
DepoMed Inc.
George Frederick Wilkinson Chief Executive Officer, President and Director
Impax Laboratories Inc.
Bruce C. Cozadd Co-Founder, Executive Chairman and Chief Executive Officer
Jazz Pharmaceuticals Public Limited Company
Vinita Gupta Chief Executive Officer, Executive Director and Member of Risk Management Committee
Lupin Limited
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALKERMES PLC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at